Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

NCT03364231 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia
Non Follicular Indolent Non-Hodgkin Lymphoma

Interventions

DRUG: Umbralisib

Sponsor

TG Therapeutics, Inc.